GlassScriptPhysician profile
Rong Huang
NPI 1437148707
$7,290.78
in general payments reported to CMS, 2019-2025
30 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $1,199 · 2021: $1,468 · 2022: $1,121 · 2023: $909 · 2024: $680 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,231.93 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,203.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $798.74 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $576.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $553.03 | 2019-2023 | |
| Lilly USA, LLC | $513.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $418.28 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $394.28 | 2019-2022 | |
| Novo Nordisk INC | $293.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $156.74 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $139.82 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $126.79 | 2019-2022 | |
| Radius Health, INC. | $123.24 | 2022-2025 | Tymlos |
| Nestle Healthcare Nutrition INC. | $100.30 | 2021-2023 | |
| Astellas Pharma US INC | $90.65 | 2023-2024 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $87.31 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $76.91 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.87 | 2022 | |
| Ironwood Pharmaceuticals, INC | $62.32 | 2019-2020 | |
| Seqirus USA INC | $37.31 | 2020-2025 | Flucelvax |
| Kyowa Kirin, INC. | $29.21 | 2022 | |
| Boston Scientific Corporation | $25.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.88 | 2024 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $24.40 | 2022 | |
| Amarin Pharma, INC. | $23.68 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.02 | 2023 | Ztlido |
| Exact Sciences Corporation | $22.91 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $21.21 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.85 | 2021 | |
| Novavax INC | $19.93 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rong Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.